Acuta Capital Partners, LLC Immunovant, Inc. Transaction History
Acuta Capital Partners, LLC
- $122 Million
- Q1 2024
A detailed history of Acuta Capital Partners, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 92,346 shares of IMVT stock, worth $2.44 Million. This represents 2.44% of its overall portfolio holdings.
Number of Shares
92,346
Previous 119,489
22.72%
Holding current value
$2.44 Million
Previous $5.03 Million
40.74%
% of portfolio
2.44%
Previous 3.92%
Shares
8 transactions
Others Institutions Holding IMVT
# of Institutions
238Shares Held
62.9MCall Options Held
1.46MPut Options Held
546K-
Vanguard Group Inc Valley Forge, PA6.48MShares$171 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$118 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$96.1 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$78.2 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$57.1 Million0.95% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.41B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...